Pharmacological Research - Modern Chinese Medicine最新文献

{"title":"A randomized double-blind placebo-controlled clinical trial on the efficacy and safety of herbal medicine San-jia-fu-mai (SJFM) in the treatment of atrial fibrillation and heart failure with preserved ejection fraction (yin depletion syndrome)","authors":"Yang Yang,&nbsp;Sizhao Li,&nbsp;Yujie Liu,&nbsp;Yunhu Song,&nbsp;Bing Hou,&nbsp;Shuaishuai Zhou,&nbsp;Dachang Xie","doi":"10.1016/j.prmcm.2025.100575","DOIUrl":"10.1016/j.prmcm.2025.100575","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the safety and efficacy of San-jia-fu-mai (SJFM) in patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF).</div></div><div><h3>Methods</h3><div>110 patients with HFpEF and AF were randomized in a double-blind, placebo-controlled trial to receive either SJFM or placebo for 12 weeks. Both groups received optimal medication therapy, including dapagliflozin. The primary endpoint was the improvement of KCCQ grade, Secondary endpoints included KCCQ score, E/e', NT-proBNP, and sRAGE, assessed at baseline and 4-week intervals for 12 weeks.</div></div><div><h3>Results</h3><div>After excluding 8 patients (4 in each group), 51 patients in each group (SJFM and placebo) completed the study and were included in the analysis. Both groups showed significant decreases in E/e′, NT-proBNP, and sRAGE at weeks 4, 8, and 12 compared with baseline (<em>P</em> &lt; 0.05). Both groups showed significant increases in KCCQ score at weeks 4, 8, and 12 compared with baseline (<em>P</em> &lt; 0.05). Furthermore, The SJFM group showed significantly greater decreases in NT-proBNP and sRAGE at weeks 4, 8, and 12 compared with the placebo group (<em>P</em> &lt; 0.05). Significant improvements in KCCQ and E/e′ were observed in the SJFM group at weeks 8 and 12. At week 12, the SJFM group showed a significantly greater improvement in KCCQ grade (94.12 % vs. 68.63 %; χ² = 9.14, <em>P</em> &lt; 0.05). No serious adverse events were reported.</div></div><div><h3>Conclusion</h3><div>SJFM demonstrated good efficacy, safety, and tolerability in patients with AF and HFpEF, suggesting its potential as a therapeutic option. The name of the trial register is “The effect of gliflozin combined with Fumai decoction on cardiac function and prognosis in patients with heart failure and atrial fibrillation with preserved ejection fraction”. The trial was registered at <span><span>http://itmctr.ccebtcm.org.cn/</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100575"},"PeriodicalIF":0.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143137971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the scope of traditional Chinese medicinal plants in battle of antibiotic resistance – A comprehensive review","authors":"Sobhanjan Bhunia,&nbsp;Sonia Mallick,&nbsp;Asif Iqbal Mondal,&nbsp;Arkaprava Saha,&nbsp;Priyanka Ray,&nbsp;Sumana Roy,&nbsp;Tamalika Chakraborty","doi":"10.1016/j.prmcm.2025.100574","DOIUrl":"10.1016/j.prmcm.2025.100574","url":null,"abstract":"<div><h3>Introduction</h3><div>The critical issue of antimicrobial resistance within healthcare settings arises primarily from the widespread use of antibiotics. This issue underscores the global concern of bacterial resistance to multiple drugs and emphasizes the growing interest in Traditional Chinese Medicine (TCM) as a potential alternative. Notably, TCM has been reported to exhibit pathogen suppression and bactericidal capabilities while demonstrating minimal therapeutic resistance.</div></div><div><h3>Methodology</h3><div>A comprehensive literature search was conducted across multiple databases, including Google Scholar, Scopus, PubMed, and Web of Science. Over 250 articles published since 2010 were initially identified, from which 230 were shortlisted based on their relevance to keywords such as “Traditional Chinese Medicine,” “Bioactive Compounds,” “Conventional Antibiotics,” “Antibiotic-Resistant Bacteria,” “Resistance Mechanisms,” and “synergistic effects” The selected 205 articles were thoroughly analyzed to compile the most recent and significant developments included in this review. All chemical structures and mechanisms were prepared using ChemDraw software, following guidelines and structural data from the PubChem database.</div></div><div><h3>Results</h3><div>TCM contains active components like flavonoids, alkaloids, phenols, and polysaccharide quinones that can impede the growth of antibiotic-resistant pathogens. Studies have examined the increasing threat and global impact of antibiotic-resistant pathogens, causes, and mechanisms of antibiotic resistance. Researches have investigated the suppressive properties of TCM plants and their bioactive substances on pathogens. Combinatorial effect of TCM plants with conventional antibiotics has garnered attention for its potential to enhance the therapeutic effectiveness against drug-resistant bacterial strains. Preclinical results demonstrate the efficacy of TCM herbs and their phytochemical compounds against antibiotic-resistant bacteria in mice. The review identified ongoing challenges in the development of TCM.</div></div><div><h3>Discussion</h3><div>This review concludes by discussing the implications of the findings. It suggests that TCM plants and their bioactive phytoconstituents show promising results in addressing conventional antibiotic resistance in bacterial pathogens. The discussion also highlights the potential for developing innovative treatment approaches to overcome resistance using TCM. This indicates a positive outlook for using TCM in combating antimicrobial resistance while acknowledging the need for further research and development in this area.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100574"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143138020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroprotective role of traditional Chinese plant extracts on Parkinson's disease; a comprehensive preclinical review","authors":"Rabia Anjum","doi":"10.1016/j.prmcm.2025.100573","DOIUrl":"10.1016/j.prmcm.2025.100573","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Parkinson's disease (PD) is a complex neurodegenerative disorder primarily characterized by gradual loss of dopaminergic neurons in the substantia nigra of the midbrain. Despite extensive research, a definitive cure that alters the progression of PD remains elusive. Herbal remedies, particularly those employed in Traditional Chinese Medicine (TCM), have been used for centuries in Asia to manage neurological conditions. Recently, there has been a renewed interest in these treatments, motivated by their potential to inform the development of pharmaceuticals that not only address PD symptoms but also modify the underlying disease mechanisms. Highlighting the urgency of this research, the increasing global prevalence of PD, expected to affect approximately 12 million individuals by 2040, underscores the urgent need for novel therapeutic strategies. Additionally, the limitations of current treatments, which often have come with significant side effects, create a compelling case for exploring the neuroprotective properties of TCM.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This review outlines the pathogenic mechanisms underlying PD including protein aggregation, mitochondrial dysfunction, ion imbalance, neuroinflammation, and oxidative stress. An extensive literature search was conducted using the PubMed and Web of Science, focusing on studies that examined Chinese herbal remedies and their key bioactive compounds in the context of PD. Articles were selected based on relevance, research rigor, and the availability of data from both in vitro and in vivo PD models. Keywords used, included “Parkinson's disease,” “Traditional Chinese Medicine,” “bioactive compounds,” “oxidative stress,” and “neuroinflammation.”&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;This review identified several TCM herbal preparations and their primary bioactive components that have shown promising effects in PD models. These compounds, including Ginsenosides, Epigallocatechin gallate, Curcumin, Sesamin, Eleutheroside B, Saponin, Theacrine, Ginkgetin, and Gypenosides, were analyzed for their mechanisms of action. The neuroprotective effects of these compounds are linked to the pathways associated with oxidative stress, inflammation, and cellular protection. Extraction methods, primarily ethanol- or water-based methods, play a significant role in isolating these active ingredients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;The findings indicate that TCM herbs and their bioactive constituents may offer valuable insights for developing PD-modifying therapies. The studied compounds demonstrated effects on essential signaling pathways related to oxidative and inflammatory stress in neurons. Understanding these mechanisms may guide the development of novel therapeutics aimed at slowing or altering PD progression. This review highlights the potential of integrating traditional herbal knowledge with modern scientific research to meet the unmet needs of patients with PD.&lt;/di","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100573"},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143137977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring synergistic benefits and clinical efficacy of turmeric in management of inflammatory and chronic diseases: A traditional Chinese medicine based review","authors":"Divya Jain ,&nbsp;Kuldeep Singh ,&nbsp;Paras Gupta ,&nbsp;Jeetendra Kumar Gupta ,&nbsp;Pankaj Kumar Sahu ,&nbsp;Sumeet Dwivedi ,&nbsp;Mukesh Chandra Sharma ,&nbsp;Shivendra Kumar","doi":"10.1016/j.prmcm.2025.100572","DOIUrl":"10.1016/j.prmcm.2025.100572","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Turmeric has been utilized for centuries in Traditional Chinese Medicine (TCM) for the management of various inflammatory and chronic diseases. Curcumin, the active component of turmeric, possesses anti-inflammatory, antioxidant, and anticancer properties. Similarly, TCM employs a holistic approach using herbal formulations, acupuncture, and dietary therapy to treat ailments. This review aims to explore the therapeutic effects of turmeric and TCM in managing inflammatory and chronic diseases, highlighting the mechanisms of action, clinical efficacy, and potential synergistic effects when used in combination.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Google Scholar, Scopus, PubMed, and Web of Science were used to search the literature related to Turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt;). The papers from the year 2000 to 2024 covering the knowledge regarding Turmeric were included. Keywords like ``Turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt;) and phytochemistry,'' ``Turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt;) and pharmacological properties,'' ``Turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt;) and Inflammatory Bowel Diseases,'' ``Turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt;) and antioxidant,'' ``Turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt;) and cardiovascular diseases,'' etc. were included in the search. A total of 150 articles were retrieved out of which a total of 85 articles were considered. An effort was made to compile pertinent writings that were only concerned with Turmeric.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The review identified significant evidence supporting the anti-inflammatory and therapeutic effects of turmeric and TCM. Turmeric (&lt;em&gt;C. longa&lt;/em&gt;) was found to modulate various molecular pathways, including NF-κB and Nrf2, reducing inflammation and oxidative stress. TCM formulations such as Huangqi (Astragalus) and Danggui (&lt;em&gt;Angelica sinensis&lt;/em&gt;) demonstrated efficacy in managing chronic conditions like rheumatoid arthritis and cardiovascular diseases. Combined use of turmeric and TCM showed enhanced therapeutic outcomes suggesting potential synergistic effects.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;div&gt;Turmeric and TCM offer promising alternatives or adjuncts to conventional treatments for inflammatory and chronic diseases. The anti-inflammatory properties of Turmeric (&lt;em&gt;C. longa&lt;/em&gt;) and holistic approach of TCM address both symptoms and underlying causes of chronic diseases. However, variability in study designs and formulations pose challenges in standardizing treatment protocols. Further clinical trials are needed to optimize dosages and combinations, ensuring safety and efficacy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Turmeric and TCM hold significant potential in the management of inflammatory and chronic diseases. Their integration into mainstream medicine could offer more comprehensive treatment options, improving patient outcomes. Future research should focus on standardizing formulations and conducting large-scale clinical trials to establish evidence-based","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100572"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143138019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visualization analysis of academic software applied to traditional Chinese medicine research based on bibliometrics methods","authors":"Hongjin Wu ,&nbsp;Shenguang Li ,&nbsp;Weiwei Dai ,&nbsp;Libo Wang ,&nbsp;Jie Zhang ,&nbsp;Chenglong Wang","doi":"10.1016/j.prmcm.2024.100571","DOIUrl":"10.1016/j.prmcm.2024.100571","url":null,"abstract":"<div><h3>Introduction</h3><div>Academic research software played an increasingly critical role in traditional Chinese medicine (TCM). Studies have explored the usage and influence of software tools. However, few studies have quantified the impact of scientific software on TCM research using CiteSpace and VOSviewer.</div></div><div><h3>Methods</h3><div>Articles related to TCM research with software applications from 1991 to 2024 were searched from the core collection database of Web of Science (WOS) and CNKI database. EndNote software was used for initial data screening. The authors, countries, institutions, keyword co-occurrence, keywords burst were analyzed using CiteSpace and VOSviewer for constructing a knowledge map.</div></div><div><h3>Results</h3><div>A total of 35,981 articles related to relevant TCM research were obtained. The publications had shown an upward trend over the past decades. In 2022, the relevant publications reached an all-time high of 2734 (CNKI) and 1873 (WOS) articles. The top three journals with the most publications were “Medicine”, “Evidence-based complementary and alternative medicine”, “Frontiers in Pharmacology”. The top three scholars with the most articles were <em>Liu Jianping, Lee Myeong Soo, and Liang Fangrong</em>. China, United States, and England were major contributors to relevant TCM research. Beijing University of Chinese Medicine, China Academy Chinese Medical and Guangzhou University of Chinese Medicine were leading institutions in this field. Keywords analysis showed that hot spots and trends in relevant research mainly focusing on systematic review, alternative medicine, acupuncture, and TCM network pharmacology.</div></div><div><h3>Discussion</h3><div>This analysis identified the most influential authors, institutions, and countries in TCM research with software applications, and provided a reference for assessing their academic impact. The analysis of keywords and software applications was useful for analyzing research hotspots and their evolution, as well as for predicting future trends.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100571"},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143138017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ameliorative effect of Yuganzi (Emblica officinalis) on chronic low-dose acrylamide-induced reproductive toxicity in male and female rats","authors":"Malarvani Thangamany ,&nbsp;Ashok Kumar Janakiraman ,&nbsp;Chandra Philip X ,&nbsp;Yin Nwe Aung ,&nbsp;Mya Thein Shin ,&nbsp;Saminathan K","doi":"10.1016/j.prmcm.2024.100569","DOIUrl":"10.1016/j.prmcm.2024.100569","url":null,"abstract":"<div><h3>Introduction</h3><div>Acrylamide (AA) is a toxic substance found in almost all our daily food items produced during the cooking process that damages the structure and affects the reproductive system's function by inducing oxidative stress, thereby increasing the health risk in humans. <em>Emblica officinalis</em> (<em>E. officinalis</em>), Yuganzi is used in Traditional Chinese Medicine (TCM) and has proven to have antioxidants that reduce oxidative stress and alleviate toxicological changes in the body. This research aims to examine the effect of <em>E. officinalis</em> on AA-induced oxidative stress and apoptosis in the reproductive systems of male and female rats.</div></div><div><h3>Methods</h3><div>A total of thirty Sprague Dawley rats were used in the study. Oral gavage was used to administer both AA and <em>E. officinalis.</em> A dose of 60 μg/kg/bw/day to cause AA toxicity and 200 mg/kg bw/day of <em>E. officinalis</em> extract was administered. Hormonal parameter analysis and histopathological analysis were done to observe the effectiveness of <em>E. officinalis</em> on AA toxicity.</div></div><div><h3>Results</h3><div>Follicular stimulating hormone (FSH), luteinizing hormone (LH), significantly decreased in acrylamide-treated females (group 2) whereas Progesterone and Testosterone showed a mild decrease in group 2 except estradiol which slightly increased. Group 3 that were treated with <em>E. officinalis</em> after the induction of AA toxicity for 8 weeks showed an increase in the hormonal parameters like the normal control group. The histopathological study showed severe degeneration of testicular cells and ovarian follicles in group 2 with interstitial oedema and haemorrhage. Group 3 showed the restoration of the AA-induced structural damage by the antioxidant properties of <em>E. officinalis</em>.</div></div><div><h3>Discussion</h3><div>This study lends credence to the bodily harm inflicted by AA on the male and female reproductive systems and the alleviative effect of <em>E. officinalis</em>. Given that <em>E. officinalis</em> did not demonstrate equivalent treatment efficacy on the testis and ovary, more research is necessary to determine whether the effectiveness is dose-dependent.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100569"},"PeriodicalIF":0.0,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143137976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antispasmodic effects and potential mechanism of the traditional chinese medicine Shaoyao–Gancao decoction on intestinal spasm in rats","authors":"Yanli Xu ,&nbsp;Renyuan Zhu ,&nbsp;Ting Chen ,&nbsp;Zhaohui Guo ,&nbsp;Tao Peng ,&nbsp;Lei Zhao","doi":"10.1016/j.prmcm.2024.100570","DOIUrl":"10.1016/j.prmcm.2024.100570","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Shaoyao–Gancao decoction (SGD) is a classic Chinese herbal formula extensively used to treat various spastic diseases in clinical settings. SGD exerts a significant antispasmodic effect with high economic value. However, the biological activity and the potential mechanisms of SGD against the intestinal spasm remain elusive. This study aimed to scientifically evaluate the antispasmodic effect of SGD on inhibiting the intestinal spasm in rats and to elucidate the multi-component and multi-targets mechanism of SGD to treat gastrointestinal spasms.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;&lt;em&gt;In vitro&lt;/em&gt; and &lt;em&gt;In vivo&lt;/em&gt; experiments were designed and conducted to verify that SGD had intestinal antispasmodic and relaxed intestinal smooth-muscle activity. In addition, the expression levels of &lt;span&gt;l&lt;/span&gt;-type voltage-gated Ca&lt;sup&gt;2+&lt;/sup&gt;channel 1.2 (Cav1.2), inositol 1,4,5-trisphosphate receptor (IP&lt;sub&gt;3&lt;/sub&gt;R), calcium/calmodulin dependent proteinase Ⅱ (CaMKΠ), myosin light chain kinase (MLCK), and ryanodine receptor (RyR2) in intestinal tissue were analyzed by Western blotting (WB). Moreover, network pharmacology analysis was performed to predict the key antispasmodic active ingredients of SGD, which were further subjected to &lt;em&gt;in silico&lt;/em&gt; studies for molecular docking.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;&lt;em&gt;In vitro&lt;/em&gt; experiments revealed that SGD had a concentration-dependent relaxant effect on the spontaneous and Ach (1 mM)-induced spastic contraction. The application of a potassium channel blocker (TEA) did not affect the SGD-mediated anti-contraction activity, wheras SGD significantly inhibited the enhancement of intestinal smooth-muscle contraction induced by Bayky8644 (an &lt;span&gt;l&lt;/span&gt;-type calcium-channel activator). Similarly, the attenuation of contraction induced by SGD can be reversed by Baky8644. In addition, the traditional Chinese medicine-based network pharmacology study revealed that SGD exerted the anti-intestinal spasm effect by acting on multiple pathways. The main active components of SGD, liquiritigenin and benzoylpaeoniflorin, had stronger binding to the voltage-gated calcium channel β2a (VGCC), calcium/calmodulin-dependent protein kinase IIB (CAMK2B), and myosin light-chain kinase-1 (MLCK-1), thereby exerting calcium channel blocker activity. Moreover, SGD exhibited antiperistaltic effects as demonstrated by &lt;em&gt;In vivo&lt;/em&gt; studies. Western blotting studies further revealed that the antispasmodic mechanism of SGD involved regulating the target proteins of calcium that mediated signalling by increasing the level of Cav1.2, IP&lt;sub&gt;3&lt;/sub&gt;R, and CaMKΠ and decreasing the level of RyR2.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;SGD exerted a significant inhibitory effect on intestinal smooth-muscle contraction, probably by altering the expression of the regulatory genes involved in the calcium-mediated smooth contraction process. Multi-component-and multi-target characteristics of S","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100570"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143137972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In-vitro and in-vivo assessment of cytotoxic potential of β-1,3 beta-glucan comprising Lentinan against glioblastoma multiforme","authors":"Sagar Trivedi ,&nbsp;Veena Belgamwar ,&nbsp;Satyendra Prasad","doi":"10.1016/j.prmcm.2024.100568","DOIUrl":"10.1016/j.prmcm.2024.100568","url":null,"abstract":"<div><h3>Introduction</h3><div>Lentinan (LNT), a bioactive β-glucan from Shiitake mushroom (<em>Lentinus edodes</em>), is traditionally used in Chinese medicine for immune support and cancer therapy. This study evaluates LNT's potential to treat glioblastoma multiforme (GBM) by exploring its immune-modulatory, antiangiogenic, cytotoxic, antioxidant, and antiproliferative effects.</div></div><div><h3>Methods</h3><div>The anti-cancer effects of LNT were assessed through <em>in-vitro</em> and <em>in-vivo</em> models. The antiangiogenic activity was measured via the CAM model, cytotoxicity through MTT and SRB assays on U87 MG cells, antioxidant potential by DPPH scavenging, and mitochondrial membrane potential using Rhodamine-123. Antimitotic and antiproliferative activities were also examined.</div></div><div><h3>Results</h3><div>LNT showed significant antiangiogenic activity at 15–20 mg/pellet (<em>p</em> &lt; 0.01) and reduced U87 MG cell viability dose-dependently, with an IC₅₀ of 96.11 ± 0.21 µg/mL at 48 h. It demonstrated 84.21 ± 1.29 % antioxidant scavenging at 100 µg/mL and lowered the mitotic index to 33 ± 1.36 % at 25 mg/mL. Mitochondrial membrane potential (MMP) showed a significant decrease in the green fluorescence (<em>p</em> &lt; 0.01). Antimitotic potential showed maximum inhibition of mitosis of 33 ± 1.36 % at 25 mg/mL along with chromosomal abnormalities on the treated root tips. In yeast cells, LNT showed substantial antiproliferative activity.</div></div><div><h3>Discussion</h3><div>These findings support LNT's traditional use in Chinese medicine and highlight its potential against GBM.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100568"},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143137980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI drug discovery tools and analysis technology: New methods aid in studying the compatibility of Traditional Chinese Medicine","authors":"Qiwu Jiang ,&nbsp;Suhan Yang ,&nbsp;Shan He ,&nbsp;Fei Li","doi":"10.1016/j.prmcm.2024.100566","DOIUrl":"10.1016/j.prmcm.2024.100566","url":null,"abstract":"<div><h3>Introduction</h3><div>The compatibility of Traditional Chinese Medicine (TCM) holds the potential for reducing toxicity and enhancing efficacy, serving as a crucial guide for the clinical application of TCM. In recent years, the development of artificial intelligence (AI) drug discovery tools has introduced novel approaches for analyzing the multichemical components of TCM, thereby saving time and efforts in experiments.</div></div><div><h3>Methods</h3><div>The keywords \"Traditional Chinese Medicine\" and \"Artificial Intelligence\", \"Traditional Chinese Medicine\" and \"drug compatibility\" were searched across various literature databases, including Web of Science, Google Scholar, PubMed, and Elsevier. Over 100 articles were reviewed, and after narrowing the selection to those focused on compatibility, the chosen studies were carefully analyzed to summarize the latest developments for this review.</div></div><div><h3>Results</h3><div>The review introduce AI drug discovery tools, including virtual screening, target prediction, ADMET prediction, and data mining, along with their roles in studying TCM compatibility. The results further provide insights of AI's application in TCM combination prediction, TCM compatibility mechanisms, and optimization of TCM compatibility ratio within the TCM compatibility research field.</div></div><div><h3>Discussion</h3><div>Traditional Chinese Medicine uses holistic formulas involving multiple components, targets, and pathways for disease treatment, but scientific explanations of these formulas are limited. AI aids TCM research by predicting combinations, mechanisms, and optimizing ratios, which improves efficiency and reducing costs. However, AI predictions may not be definitely accurate, and traditional expertise is still essential for validation. Future applications of AI in TCM require improved tools and collaboration between AI and TCM researchers.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100566"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143138018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated network pharmacology, bioinformatics, and experimental approach to explore the mechanism of honokiol liposomes against glioblastoma","authors":"Fang Cheng ,&nbsp;Yingfang Ma ,&nbsp;Neng Qiu,&nbsp;Yutao Yang,&nbsp;Zhichun Shen,&nbsp;Xintian Lai,&nbsp;Jianhua Ge,&nbsp;Yingjia Guo","doi":"10.1016/j.prmcm.2024.100567","DOIUrl":"10.1016/j.prmcm.2024.100567","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Honokiol (HK), a bioactive compound isolated from &lt;em&gt;Magnolia officinalis Rehd. et Wils.&lt;/em&gt; (commonly called &lt;em&gt;Houpu&lt;/em&gt; Magnolia or Magnolia-bark), has demonstrated significant anticancer potential across various malignancies. Despite its promising therapeutic effects, the clinical application of honokiol has been hampered by its low bioavailability and poor aqueous solubility. To address these limitations, we have investigated the use of liposomal drug delivery systems. Preliminary results from our phase I clinical trials have shown encouraging outcomes: patients with recurrent glioblastoma multiforme (GBM) treated with honokiol liposomes exhibited a longer median overall survival (15 months) compared to those receiving bevacizumab (9.3 months), a standard treatment option. While these initial findings are promising, the precise mechanisms underlying the enhanced efficacy of honokiol when delivered via liposomes remain to be fully elucidated.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Various databases including TCMSP, CTD, BATMAN-TCM, PharmMapper, and SwissTargetPrediction were searched to identify honokiol targets and GBM targets were obtained from GeneCards, OMIM, and DisGeNET disease databases. The component-disease intersection target protein-protein interaction (PPI) network was constructed using String database and Cytoscape3.9.1. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of major intersection targets was performed using DAVID. Differential expression targets among the major intersection targets were analyzed using GEPIA, HPA, ROC Plotter, and TIMER databases. Finally, molecular simulation docking verification was conducted using Auto Dock4.2. Finally, we conducted targeted experiments to validate and assess key biological processes, molecular functions, and signaling pathways identified through our comprehensive network pharmacology analysis. Our approach included in vitro studies focusing on proliferation, cell cycle progression, and apoptosis, as well as in vivo experiments examining inflammatory responses.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Network pharmacological screening identified 31 major intersecting targets of honokiol and GBM. GO analysis revealed significant enrichment (&lt;em&gt;P&lt;/em&gt; &lt; 0.05) in 316 biological processes, 38 cellular components, and 70 molecular functions. KEGG pathway analysis highlighted significant correlations with cancer pathways, metabolic disease pathways, and inflammatory signaling pathways. Further bioinformatic analysis pinpointed 16 core targets significantly affecting GBM, with molecular docking confirming honokiol's spontaneous binding to these targets. Both in vitro and in vivo experiments substantiated these findings, demonstrating that honokiol and its liposomal formulation effectively suppress GBM cell proliferation, induce cell cycle arrest and apoptosis, while significantly reducing inflammatory cytokine express","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100567"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143137979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}